Clinical utility of targeted treatments in the management of epithelial ovarian cancer
Cheryl Twu,1 Ernest S Han21Department of Women’s Health, Arrowhead Regional Medical Center, Colton, CA, USA; 2Division of Gynecologic Oncology, City of Hope, Duarte, CA, USAAbstract: Epithelial ovarian cancer is typically found in its advanced stages, where a combination of surgical de...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/174964cf40d8465eaa72fc7fe6ebb42c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:174964cf40d8465eaa72fc7fe6ebb42c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:174964cf40d8465eaa72fc7fe6ebb42c2021-12-02T08:54:50ZClinical utility of targeted treatments in the management of epithelial ovarian cancer1177-54751177-5491https://doaj.org/article/174964cf40d8465eaa72fc7fe6ebb42c2012-07-01T00:00:00Zhttp://www.dovepress.com/clinical-utility-of-targeted-treatments-in-the-management-of-epithelia-a10521https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Cheryl Twu,1 Ernest S Han21Department of Women’s Health, Arrowhead Regional Medical Center, Colton, CA, USA; 2Division of Gynecologic Oncology, City of Hope, Duarte, CA, USAAbstract: Epithelial ovarian cancer is typically found in its advanced stages, where a combination of surgical debulking and platinum/taxane-based chemotherapy is recommended. Although over 70%–80% of patients achieve remission, a significant proportion develop recurrence of their disease. Additional cytotoxic chemotherapy, as well as surgery, is typically used to manage disease recurrence. Therapies that target specific pathways in cancer cells are rapidly developing in the laboratory and are increasingly being studied in patients with ovarian cancer. We review the current status of novel therapies in the management of epithelial ovarian cancer.Keywords: angiogenesis, polyadenosine ribose pathway inhibitors, epidermal growth factor receptor, folate inhibitorsTwu CHan ESDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 233-244 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Twu C Han ES Clinical utility of targeted treatments in the management of epithelial ovarian cancer |
| description |
Cheryl Twu,1 Ernest S Han21Department of Women’s Health, Arrowhead Regional Medical Center, Colton, CA, USA; 2Division of Gynecologic Oncology, City of Hope, Duarte, CA, USAAbstract: Epithelial ovarian cancer is typically found in its advanced stages, where a combination of surgical debulking and platinum/taxane-based chemotherapy is recommended. Although over 70%–80% of patients achieve remission, a significant proportion develop recurrence of their disease. Additional cytotoxic chemotherapy, as well as surgery, is typically used to manage disease recurrence. Therapies that target specific pathways in cancer cells are rapidly developing in the laboratory and are increasingly being studied in patients with ovarian cancer. We review the current status of novel therapies in the management of epithelial ovarian cancer.Keywords: angiogenesis, polyadenosine ribose pathway inhibitors, epidermal growth factor receptor, folate inhibitors |
| format |
article |
| author |
Twu C Han ES |
| author_facet |
Twu C Han ES |
| author_sort |
Twu C |
| title |
Clinical utility of targeted treatments in the management of epithelial ovarian cancer |
| title_short |
Clinical utility of targeted treatments in the management of epithelial ovarian cancer |
| title_full |
Clinical utility of targeted treatments in the management of epithelial ovarian cancer |
| title_fullStr |
Clinical utility of targeted treatments in the management of epithelial ovarian cancer |
| title_full_unstemmed |
Clinical utility of targeted treatments in the management of epithelial ovarian cancer |
| title_sort |
clinical utility of targeted treatments in the management of epithelial ovarian cancer |
| publisher |
Dove Medical Press |
| publishDate |
2012 |
| url |
https://doaj.org/article/174964cf40d8465eaa72fc7fe6ebb42c |
| work_keys_str_mv |
AT twuc clinicalutilityoftargetedtreatmentsinthemanagementofepithelialovariancancer AT hanes clinicalutilityoftargetedtreatmentsinthemanagementofepithelialovariancancer |
| _version_ |
1718398287510241280 |